Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): A prospective phase II trial (NCT04161833)

Background: Aromatase Inhibitors (AIs) are recommended for the adjuvant treatment of hormone receptor positive breast cancers in the postmenopausal population. Approximately 25% of postmenopausal women on AI report arthralgia, skeletal, and muscle pain as main cause of discontinuation of therapy. OPERA ® (GAMFARMA srl, Milan, Italy) is a new dietary supplement where α-Lipoic acid (240 mg), Boswellia serrata (40 mg), Methylsulfonylmethane (200 mg) and Bromelain (20 mg) are combined together in a single hard-gelatin capsule to be taken once a day.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: I. Desideri, S. Lucidi, P. Garlatti, V. Lorenzetti, C. Ciabatti, F. Terziani, V. Scotti, P. Bonomo, G. Francolini, I. Meattini, L. Livi Tags: POSTERS A: Supportive and Palliative Care Including End of Life Treatment Source Type: research